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Abstract 
Ibuprofen–polyethylene glycol (PEG) conjugates (PEG-Ibu) were prepared and 
their potential as a prolonged release system was investigated. Two PEG-Ibu 
conjugates were synthesized from Ibuprofen and PEG with two different 
molecular weights by esterification in the presence of DCC and DMAP. The 
PEG-Ibu conjugates were characterized by FT-IR, 
1H NMR, Mass spectroscopy 
and DSC analysis.    The solubility study in aqueous system showed an increase 
in solubility of conjugates. The dissolution / hydrolysis studies showed a specific 
acid–base catalysis pattern dependent on the pH of the medium. This indicated 
a good chemical stability in aqueous buffer solution of acidic medium and the 
extended release behavior was found in both prodrugs after 9 hour. The results 
demonstrate that, in the same condition, the rate of hydrolysis for PEG4000-Ibu is 
slower than other. The Writhing induced by acetic acid experiment and paw 
edema test after oral administration showed that both conjugates had extended 
analgesic and anti-inflammatory effects compared with Ibuprofen. These results 
suggest that PEG-Ibu could be a promising NSAID prodrug with an extended 
pharmacological effect owing to delayed-release of parent drug.  
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Introduction 
Non-steroidal anti-inflammatory drugs (NSAIDs) are usually poorly soluble in water [1] and 
they frequently cause gastrointestinal side effects such as gastric ulceration, bleeding and 
perforation [2, 3]. Ibuprofen is a non-steroidal anti-inflammatory drug with well known anti-
inflammatory, antipyretic and analgesic properties. Chemically it is 2-(4-iso-butylphenyl)-
propanoic acid and is poorly soluble in water [4, 5]. It is most commonly administered 
orally and is rapidly absorbed to reach its maximal plasma concentration with in 2 hrs [6]. 
However, it has a short biological half-life of 2 hrs, which means that frequent doses are 
required to maintain the therapeutic efficacy over extended time periods. 
These problems can be solved by the preparation of polymeric prodrug backbones which 
can contain drugs in a physically bound (dissolved, dispersed, included or adsorbed) state 
or by true chemical linkages along the polymer backbone or as side groups. These latter 
systems, in which drugs are delivered by chemically or biologically induced cleavage of the 
covalent bonds, allow one to achieve a more constant release of the drug for long periods 
of time. The use of polymers as prodrugs of bioactive agents can thus decrease the 
required dose, and then the toxicity of the drug, making its solubility and therapeutic 
efficiency better [7]. In modern era, some NSAIDs such as Ibuprofen, Indomethacin, 
Ketoprofen and Diclofenac were covalently attached to various polymer backbones and 
their hydrolysis studied.  
The biologically active drug and a polymer conjugation is one of the numerous methods for 
changing and controlling the pharmacokinetics, biodistribution and often toxicity of these 
compounds [8–13]. The preparation of a drug-polymer conjugate has been reported widely 
in many reviews [14–21]. Recently, polymeric prodrugs having Ibuprofen pendent groups 
were prepared by the free radical polymerization of new polymerizable acrylic monomer 
with various co monomers. For controlled drug release, this Ibuprofen-dextran ester 
prodrug improved Ibuprofen solubility and achieving prolonged release properties [20–22]. 
α-methyl, ethyl and propyl glucopyranoside esters conjugate of Ibuprofen and glyceride 
prodrugs was reported to have less ulcerogenicity with better anti-inflammatory/analgesic 
action than their parent drug when administered orally [24,  25]. A conjugate with 
β-cyclodextrin was prepared by covalent bonding to one of the primary hydroxyl groups of 
β-cyclodextrin for enhanced Solubility and Dissolution [26, 27]. Drugs that contain reactive 
functional groups such as carboxyl or hydroxyl groups can be converted to a wide variety 
of polymerizable derivatives.  
In this study poly (ethylene glycol) is being used as the carrier polymer, because it is 
known to be non-toxic, non-antigenic, non-teratogenic, non-immunogenic, biocompatible, 
available in variety of molecular weights, linear, uncharged, and amphiphilic polymer, 
soluble in water and in most organic solvents and has solubilizing properties, rapidly 
eliminated from the body, and has been approved for a wide range of biomedical 
applications [15–18, 28]. Considering all these general properties and advantages of PEG, 
in this research work, we selected PEG as a polymer drug carrier and Ibuprofen as a small 
molecular drug which was covalently linked to PEG for preparing PEG–Ibu prodrug. By 
using PEGs with different molecular weights, two polymer prodrugs were synthesized, and 
their detailed molecular structures were characterized via 
1H NMR and FTIR techniques. 
This study aimed to suggest that PEG-Ibu prodrug obtained could be a promising NSAID 
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prodrugs in various media demonstrated that extended pharmacological effect owing to 
delayed-release of parent drug for Ibuprofen has been achieved significantly. 
Experimental 
Material 
Ibuprofen was obtained from Unisule, sonipat. 4-Dimethylaminopyridine (DMAP) and 
N,N'-dicyclohexylcarbodiimide (DCC) were obtained from Spectrochem, Mumbai. 
Poly(ethylene glycol) with a molecular weight of 600 and 4000 was obtained from E.Merck, 
Mumbai. All other chemicals were of reagent grade and used without further purification. 
Analytical methods 
The infrared absorption spectra of the Ibuprofen, PEG and PEG-Ibu were obtained using a 
FT-IR spectrophotometer (FT/IR- 8400 S, Shimadzu, Japan). The samples were pressed 
into a potassium bromide pellet before obtaining their IR absorption spectra. The 
1H NMR 
spectra were obtained on a Bruker 400 Spectrometer (Bruker Avance-II 400 NMR 
Spectrometer SAIF, Panjab University, Chandigarh). Ultraviolet–visible spectra were 
recorded on a Thermospectronic UV 1 Double beam spectrophotometer (Merck, Mumbai). 
DSC (Shimandzu corporation, DSC-TA-GOWS-(U220 230V), Serial no. C-30454700909) 
was used to determine the thermal behaviors of Ibuprofen and prodrugs.  
Methods 
Preparation and characterization of the PEG-Ibuprofen conjugate  
Preparations of the PEG600-Ibuprofen conjugate (PEG-Ibu)  
Poly (ethylene glycol)600 5.38 gm. (8mmol) and DCC 6.592 gm. (16mmol) were dissolved 
in methylene chloride followed by the addition of Ibuprofen 3.3gm (16mmol) and DMAP 
0.293gm. (2.4mmol). The mixture was stirred, and a white precipitate of dicyclohexylurea 
(DCU) was formed after 15–30 min. The reaction was monitored by thin layer 
chromatography (TLC). After approximately 6–8 h, the precipitate was filtered and the 
filtrate was evaporated to dryness. The resulting residue was dissolved in acetone, filtered 
to further remove any DCU, and evaporated again. 10% sodium bicarbonate was used to 
separate the PEG–Ibu from free Ibuprofen. Column chromatography was used to separate 
the PEG–Ibu from the reaction mixture. In order to remove the DMAP, a 
methanol/methylene chloride (9/91): hexane/ethyl acetate (1/2) mixture at a ratio of 20:1 
was used as the mobile. The purified products were dried under vacuum. The pure 
PEG600–Ibu conjugate with the yield of 60.49% was obtained. The fact that there was no 
free drug of Ibu existing in polymer prodrug was confirmed by thin layer chromatography 
and DSC measurements.  
Preparations of the PEG4000-Ibuprofen conjugate (PEG4000-Ibu) 
The same procedure was used to prepare PEG4000-Ibu as mentioned above. In this case, 
Poly (ethylene glycol)4000 8 gm. (2mmol) and DCC 1.648 gm. (4mmol) were dissolved in 
dichloromethane followed by the addition of 2-(4-isobutylphenyl) propanoic acid 
(Ibuprofen) 0.825gm. (4mmol) and DMAP 0.1466 gm. (0.6mmol). Yield: 57.57% 
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Determination of Drug Solubility 
To determine the drug solubility, an excess amount of pure Ibuprofen, PEG4000-Ibu 
conjugate and PEG600-Ibu conjugate were added to distilled water and Phosphate Buffer 
(pH 7.4). This suspension was stirred at room temperature for 24 hours with a Rota spin 
test tube Roter. After that the containers (test tubes) were left overnight for saturation. 
Then these saturated solutions were centrifuged at 10000 rpm the help of macro 
centrifuge and the supernatant was filtered via Whatman filter paper. The concentration of 
Ibuprofen was determined spectrophotometrically at 222 nm [29–31]. 
Drug release tests via hydrolysis 
The hydrolysis rates of the synthesized conjugates were studied in vitro in artificial gastric 
juice pH 1.2 and in Phosphate buffer solution pH 7.4. The reaction was monitored by UV- 
Visible spectrophotometer for the increase in concentration of free drug with time.  
(a) Hydrolysis in 0.2 M hydrochloric acid buffer (pH 1.2) 
PEG600-Ibu and PEG4000-Ibu (wt. equivalent to 10 mg of Ibuprofen) were taken and 
introduced in 900 ml HCl buffer (pH 1.2) taken in the separate baskets in USP dissolution 
apparatus type-I and were kept in a constant temperature bath at 37 ± 1 °C. The solutions 
were occasionally stirred and 5 ml aliquot of both conjugates were withdrawn at various 
time intervals and were transferred to 10 ml volumetric flasks. The sink conditions were 
maintained by replacement of equal volume of fresh dissolution medium. Standerd curve 
were made by pure Ibuprofen in buffer solution using UV spectrophotometer at 222nm. 
The concentration of Ibuprofen released was analyzed and calculated by comparing the 
slope of standard curve at 222nm. Experiments was repeated three times. 
(b) Hydrolysis in 0.2 M phosphate buffer (pH 7.4) 
Same procedure as described in (a) was followed for PEG600-Ibu and PEG4000-Ibu, where 
instead of HCl buffer, phosphate buffer pH 7.4 was used. Percentage of drug released was 
calculated. Studies were carried out in triplicate. 
Biological Evaluation 
All the animals were obtained from the animal house of the Department of Pharmacology, 
B.R. Nahata College of Pharmacy, Mandsaur and its animal facility is approved by 
CPCSCA (Reg. No. 918/ac/05/CPCSEA). The experimental protocols for the same have 
been approved by Institutional Animal Ethics Committee. The analgesic activity was 
carried out on Swiss albino mice by the Siegmund et al. method; anti-inflammatory activity 
of the compounds was carried out on Wistar rats by the Winter et al. method [25, 32]. 
Writhing Induced by Acetic Acid  
Analgesic activity was carried out by using acetic acid induced writhing method in Swiss 
albino mice (25–30 g) of either sex. A 1% v/v solution of acetic acid was used to induce 
writhing. Test compounds were administered orally 3 h prior to acetic acid injection. 
Number of writhing for 10 min in control and test compounds were counted and compared. 
To evaluate the analgesic activity of the conjugates 4 groups of animals (n = 6) were 
examined. A first group of rats was used as a control receiving vehicle 5 ml kg
−1, while 
group II received Ibuprofen (20 mg kg
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and PEG4000-Ibu conjugate (52.60 mg kg
−1 and 214 mg kg
−1 respectively), where the dose 
of conjugate was molecularly equivalent to Ibuprofen. A stock solution of 0.2, 0.52 and 
2.14 mg ml
−1 was prepared as a homogeneous suspension in aqueous solution of sodium 
CMC (0.5% w/v) and each animal received 2.0–2.2 ml of the respective drugs orally. 
Acetic acid was administered intraperitoneally 1 ml/100 g body weight of the animal. 
Analgesic activity was measured as percent decrease in writhing in comparison to control. 
The percent Inhibition was calculated using the following equation:  
100
control   in    writhings of   number
test   in    writhings of   number
  – 100     Inhibition   % × =  
Carrageenan-Induced paw edema 
The anti-inflammatory activity was evaluated using carrageenan-induced paw edema on 
rat method. To evaluate the anti-inflammatory activity of the conjugates 4 groups (n = 6) of 
Wistar rats (150–200 g) were examined. A first group of rats was used as a control without 
using the drug, group II received Ibuprofen 20 mg kg
–1, received PEG600-Ibu conjugate and 
PEG4000-Ibu conjugate (52.60 mg kg
−1 and 214 mg kg
−1 respectively), where the dose was 
molecularly equivalent to the Ibuprofen. A stock solution of 0.2, 0.52 and 2.14 mg ml
−1 was 
prepared as a homogeneous suspension in aqueous solution of sodium CMC (0.5% w/v) 
and each animal received 2.0- 2.2 ml of the respective drugs orally. Thirty minutes after 
administration of drugs, each rat received a subplanter injection of 0.1 ml of 1% 
carrageenan solution in its left hind paw. The swelling volume of the paw was measured 
before (time 0) and at 0.5, 1, 2, 3, 4, 24 h after the carrageenan injection. The 
measurement of the hind paw volume was carried out using an Ugo Basile 
Plethysmometer before any treatment (Vo) and in any interval (Vt) after the administration 
of the drugs. The percentage increase in the paw volume was calculated from the normal 
paw volume. The percentage of swelling inhibition was calculated using: 
  100
)    – Vo (Vt  
)    – Vo  Vt (  –  )    – Vo t  V  (
    (%)   Inhibition
control
treated control × =  
(Vt and Vo relates to the average volume in the hind paw of the rats (n = 6) before any 
treatment and after anti-inflammatory agent treatment, respectively. 
Statistical Analysis 
All the results are expressed as mean ± S.E.M. Statistical evaluation was performed using 
analysis of variance followed by Dunnet’s t -test for sub group comparison. A 
P value <0.001 was considered significant. 
Results and discussion 
Preparation of PEG-Ibu conjugate 
In this work, PEG-Ibu was synthesized by the esterification of the carboxyl group of 
Ibuprofen with the hydroxyl group of PEG at room temperature, as shown in Fig. 1. 364  A. Nayak and A. Jain:   
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Fig. 1.  Synthesis of the PEG-Ibuprofen conjugate 
The esterification was performed using DCC as the coupling agent and DMAP as a 
catalyst [33]. The conjugation between Ibuprofen and PEG was confirmed by FT-IR and 
1H 
NMR. The position of peak on IR spectrum for PEG4000-Ibu conjugate was assigned as 
follows; IR (pellet): 2876.8, 1731, 1512, 1113.cm
−1. When conjugated, the hydroxyl groups 
of Ibuprofen and PEG are expected to disappear due to the esterification process. The 
carbonyl peak of Ibuprofen appearing at 1710 cm
−1 due to intermolecular hydrogen 
bonding will be shifted to a higher frequency after conjugation with PEG. In addition, larger 
and sharper aliphatic stretching band of C-H will appear, due to the increased number of 
C-H bonds by PEG. As shown in Fig. 2, there was no hydroxyl peak in the PEG4000 
spectrum and the carbonyl peak shifted to 1731 cm
−1. Also, the larger and sharper C-H 
stretching band appeared at 2876.8 cm
−1. 
At room temperature, PEG600-Ibu was oily, and the PEG4000-Ibu was solid. All the 
conjugates were soluble in water and organic solvents such as ethanol, chloroform and 
dichloromethane. Fig. 3  shows the chemical shift of the PEG4000-Ibu measured by 
1H 
NMR. PEG4000-Ibu: 
1H NMR (400 MHz, CDCl3, ppm): δ 0.90 [d, 12H,-CH(CH3)2], 1.47 [d, 
6H, -CHCH3], 1.80–1.87 [m,2H, -CH(CH3)2], 2.42 [d, 2H, -CH2], 3.38–3.83 [m, 
-O(OCH2CH2)n], 3.69–3.75 [q, 2H, -CHCH3], 4.17–4.24 [m, 4H, CO2CH2], 7.07–7.29 [m, 
8H, ArH]. The pegylation was confirmed by disappearance of the signal of the carboxylic 
acid at 11.23 ppm and appearance of -CO2CH2-protons at 4.2 ppm.   In Vitro and In Vivo Study of Poly(ethylene glycol) Conjugated Ibuprofen to Extend the Duration …  365 
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Fig. 2.  FTIR OF PEG4000-Ibu conjugate 
The position of each peak in IR and NMR spectrum for PEG600-Ibu: IR (KBr pellet): 2885.8, 
1734.2, 1467.2, 1114.1 cm
−1. 
1H NMR (400 MHz, CDCl3, ppm): δ 0.89 [d, 12H, 
-CH(CH3)2], 1.46 [d, 6H, -CHCH3], 1.53–1.58 [m, 2H, -CH(CH3)2], 2.44 [d, 2H, -CH2], 3.54–
3.72 [m, -O(OCH2CH2)n], 3.65–3.72 [q, 2H, -CHCH3], 4.10–4.19 [m, 4H, CO2CH2], 7.06–
7.21 [m, 8H, ArH]. 
 
Fig. 3. 
1HNMR spectra of PEG 4000–Ibuprofen Conjugate 
Additionally, thin layer chromatography, DSC was used for determining free Ibuprofen in 
polymer prodrug, and the results as shown in Fig. 4. Pure Ibuprofen melting point was at 
79.69°C on its DSC thermogram, and PEG4000-Ibu was at 58.73°C. However no peak was 
visible near the Ibuprofen’s melting point for the polymeric conjugate thermogram. 366  A. Nayak and A. Jain:   
Sci Pharm. 2011; 79: 359–373 
 
Fig. 4.  DSC-thermogram of pure Ibuprofen (a), PEG4000-Ibu conjugate (b) 
Aqueous Solubility  
Physicochemical parameter such as aqueous solubility has been shown to influence 
membrane flux, therapeutic activity, and pharmacokinetic profiles of medicines. The 
solubility of Ibuprofen in distilled water has been previously found to be 10.57 mcg/mL. In 
this study, the solubility of PEG600-Ibuprofen and PEG4000-Ibuprofen conjugates in distilled 
water were 24.48 mcg/mL and 50.57 mcg/mL respectively. The solubility of Ibuprofen in 
phosphate buffer (pH 7.4) has been previously found to be 25.16 mcg/mL and solubility of 
PEG600-Ibuprofen and PEG4000-Ibuprofen conjugates in phosphate buffer (pH 7.4) were 
41.97 mcg/mL and 57.21 mcg/mL respectively. As may be noted in Fig. 5 and 6, Ibuprofen 
water solubility was less while for PEG600-Ibuprofen and PEG4000-Ibuprofen conjugates an 
increase of this parameter was observed. From the solubility data we can conclude that 
PEG4000-Ibu conjugate is more hydrophilic in nature. 
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Fig. 5.  Comparative Solubility Study in Distilled Water 
 
Fig. 6.  Comparative Solubility in Phosphate Buffer (pH 7.4) 
In vitro Hydrolysis Studies 
In order to obtain some preliminary information about the potential use of the PEG-Ibu as a 
drug delivery system for a prolonged release, hydrolysis process for two prodrugs is 
studied in buffer solutions at pH 1.2 and 7.4. This study shows whether the prodrugs 
hydrolyze in these buffer solutions and to what extent, providing an idea of the fate of the 
prodrug in-vivo. 
On the one hand comparison of the release profile of Ibuprofen conjugates (PEG600-Ibu 
and PEG4000-Ibu conjugates) in 0.2 M HCl buffer (pH 1.2) revealed that PEG600-Ibu and 
PEG4000-Ibu conjugates were hydrolysed to an extent of 64.35% and 43.9% at pH 1.2 after 
8 hrs and this percentage still increases by time reaching 87.26% and 71.2% after 24 hrs 
for PEG600-Ibu and PEG4000-Ibu conjugate respectively (Fig. 7). 
 
Fig. 7.  Comparative release of Ibuprofen in HCl buffer (pH 1.2) 
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On the other hand, Ibu-release from the conjugates in 0.2 M phosphate buffer (pH 7.4) 
amounted to 83.1% (PEG600-Ibu) and 71.2% (PEG4000-Ibu) after 8 hrs and further 
increased 98.3 and 89.0% in 24 hrs for PEG600-Ibu and PEG4000-Ibu conjugate respectively 
(Fig. 8). The hydrolysis rate of Ibuprofen from PEG600-Ibu and PEG4000-Ibu conjugates was 
calculated to be 8% and 5% per hour at pH 1.2 and 16% and 9% at pH 7.4, respectively. 
This study shows that hydrolysis rate of Ibuprofen from PEG4000-Ibu is slower than other. 
The dissolution / hydrolysis studies of ester prodrugs indicated a better chemical stability in 
aqueous buffer solution of acidic pH 1.2 than at nearly neutral pH 7.4. In case of oral 
administration, this study implies that about 88-90 % intact conjugate reach the intestine 
provided a mean gastric residence time of the conjugates for two hours. 
Another aspect was also cleared that hydrolysis of conjugates decreased with increase in 
length of PEG and the extended release behavior was found in both conjugates in both pH 
1.2 and 7.4 buffer solutions after 8 hrs. to 24 hrs. (Figs. 7 and 8).  
 
Fig. 8.  Comparative Release of Ibuprofen in Phosphate Buffer (pH 7.4) 
Analgesic Activity  
Analgesic activity was carried out by using acetic acid induced writhing method in Swiss 
albino mice (25–30 g) of either sex. A 1% v/v solution of acetic acid was used to induce 
writhing. Test compounds were administered orally 3 h prior to acetic acid injection. The 
PEG600-Ibu conjugate and PEG4000-Ibu conjugate showed analgesic activity comparable to 
the parent drug. The percent protection in mice brought about by administration of the 
drugs. In writhing model, Ibuprofen and all its prodrugs (PEG600-Ibu conjugate and 
PEG4000-Ibu conjugate) presented remarkable reduction of writhing number if compared to 
control group (Fig. 9). 
Ibuprofen administrated 3 hr. prior to testing produced a significant decrease (59.61%) in 
writhing number versus control values Moreover, both conjugate PEG600-Ibu conjugate 
and PEG4000-Ibu conjugate were equally effective in reducing the writhing response 
(57.10% and 59.02% respectively) at molecular equivalent quantity. however, no 
appreciable difference could be observed among all prodrugs with respect to their 
analgesic activity. 
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Effect of Ibuprofen and its Conjugates
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Fig. 9.  Effect of ibuprofen and its conjugates (PEG600-Ibu and PEG4000-Ibu) on acetic 
acid induced writhing in mice. Data represent mean values (±S.D.) and percent 
inhibition (%) compared to the control animals. Statistical differences versus 
control group are indicated by asterisks {N = 6, one-way ANOVA, (p< 0.05 (*), 
p< 0.01 (**) and p< 0.001 (***)}. 
Anti-inflammatory Activity 
Table 2 shows the effect of Ibuprofen, PEG600-Ibu and PEG4000-Ibu conjugates on the 
volume of acute inflammatory paw edema in rats caused by carrageenan after oral 
administration. Although the peak anti-inflammatory effects of PEG600-Ibu conjugate and 
PEG4000-Ibu conjugate occurred later than Ibuprofen, but it exhibited a significantly 
extended anti-inflammatory activity compared with Ibuprofen. The maximum anti-
inflammatory activity of prodrugs (PEG600-Ibu conjugate and PEG4000-Ibu conjugate) was 
observed at 3-4 h and remained practically constant up to 8 h. The anti-inflammatory 
activity of free Ibuprofen however decreased with time.  
Statistical significance testing using one way analysis of variance showed that the anti-
inflammatory activity of ibuprofen and prodrugs were effective in comparison with the 
control group. However, differences in the potency of anti-inflammatory activity of the 
prodrugs compared to the free ibuprofen were observed over a long period (8 h). Thus 
PEG600-Ibu conjugate and PEG4000-Ibu conjugate were investigated to be a suitable 
promoiety for Ibuprofen.  
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Tab. 2.  Percentage of Inhibition Caused by Ibuprofen and Its Conjugates in 
Carrageenan-Induced edema in Wistar rats (150–200 g)  
Treatment Dose 
(mg/kg) 
1 hr.  2 hr  3 hr  4 hr  8 hr  24 hr 
Control –  0.59 ± 
0.005 
0.68 ± 
0.007 
0.48 ± 
0.009 
0.43 ±  
0.011 
0.32 ±  
0.005 
0.27 ± 
0.006 
Standard 20  0.33 ± 
0.013**
0.48 ± 
0.017**
0.38 ± 
0.013**
0.24 ±  
0.009** 
0.15 ±  
0.010
ns 
0.03 ± 
0.013
ns 
PEG600-Ibu Conjugate  52.60  0.22 ± 
0.008***
0.33 ± 
0.007***
0.43 ± 
0.012**
0.37 ±  
0.014** 
0.30 ±  
0.009** 
0.17 ± 
0.010**
PEG4000-Ibu Conjugate  214  0.25 ± 
0.011**
0.36 ± 
0.010
** 
0.45 ± 
0.018**
0.40 ±  
0.014** 
0.34 ±  
0.007** 
0.20 ± 
0.011**
Value are expressed in mean ± SEM; p< 0.05 (*), p< 0.01 (**), and p< 0.001 (***); One-way Anova followed 
by Dunnet’s test. 
 
Acknowledgements 
The authors thank the B. R. Nahata College of pharmacy for financial support.  
Authors’ Statements 
Competing Interests  
The authors declare no conflict of interest.  
Animal Rights  
The institutional and international guide for the care and use of laboratory animals was 
followed. See the methods part for details.  
References  
[1]  Zhao X, Tao X, Wei D, Song Q.  
Synthesis and Study of Controlled Release of Ibuprofen from the New Acrylic Type Polymers.  
Eur J Med Chem. 2006; 41: 1352–1358. 
doi:10.1016/j.ejmech.2006.05.014 
[2]  Guyton CA, Hall JE.  
In: Textbook of Medical Physiology. 
Harcourt Asia Pte. Ltd. 1998: 846. 
[3]  Khan MSY, Akhter M.  
Synthesis, pharmacological activity and hydrolytic behavior of glyceride prodrugs of ibuprofen.  
Eur J Med Chem. 2005; 40: 371–376.  
doi:10.1016/j.ejmech.2004.11.009 
[4] Babazadeh  M. 
Synthesis and study of controlled release of Ibuprofen from the new acrylic type polymers. 
Int J Pharm. 2006; 316: 68–73.  
doi:10.1016/j.ijpharm.2006.02.032   In Vitro and In Vivo Study of Poly(ethylene glycol) Conjugated Ibuprofen to Extend the Duration …  371 
Sci Pharm. 2011; 79: 359–373 
[5]  Giammona G, Puglisi G, Carlisi B, Pignatello R, Spadaro A, Caruso A.  
Polymeric prodrugs: poly (N-hydroxyethyl)-dl-aspartamide as a macromolecular carrier for some non-
steroidal anti-inflammatory agents. 
Int J Pharm. 1989; 57: 55–62. 
doi:10.1016/0378-5173(89)90263-9 
[6] Borne  RF.   
Nonsteroidal Anti-inflammatory Agents.  
In: Foye’s Principles of Medicinal Chemistry. 
Philadelphia: Lippincott Williams and Wilkins, 2005: 771. 
[7]  Zacchigna M, Luca GD, Boccu E. 
Synthesis, Chemical and Enzymatic Stability of New Poly (ethylene glycol)-Acyclovir Prodrugs.  
Farmaco. 2002; 57: 207–214.  
doi:10.1016/S0014-827X(01)01193-4 
[8]  Duncan R, Kopecek J.  
Soluble synthetic polymers as potential drug carriers.  
Adv Polym Sci. 1984; 57: 53–10.  
doi:10.1007/3-540-12796-8_10 
[9]  Cavallaro G, Licciardi M, Caliceti P, Salmaso S, Giammona G.  
Synthesis, physico-chemical and biological characterization of a paclitaxel macromolecular prodrug.  
Eur J Pharm Biopharm. 2004; 58: 151–159.  
doi:10.1016/j.ejpb.2004.02.012 
[10]  Cavallaro G, Maniscalco L, Caliceti P, Salmaso S, Semenzato A, Giammona G.  
Glycosilated macromolecular conjugates of antiviral drugs with a polyaspartamide. 
J Drug Target. 2004; 12: 593–605.  
doi:10.1080/10611860400013477 
[11]  Fuertges F, Abuchowski A.  
The clinical efficacy of poly (ethylene glycol)-modified proteins. 
J Control Release. 1990; 11: 139–148. 
doi:10.1016/0168-3659(90)90127-F 
[12]  Nichifor M, Schacht EH, Seymour LW.  
Macromolecular prodrugs of 5-fluorouracil. 2. Enzymatic degradation. 
J Control Release. 1996; 39: 79–92. 
doi:10.1016/0168-3659(95)00141-7 
[13]  Duncan R, Seymour LW, O’Hare KB, Flanagan PA, Wedge S, Wedge IC, Ulbrich K, Strohalm J, 
Spreafico F, Grandi M, Ripamonti M, Farao M, Suarato A.  
Preclinical evaluation of polymer-bound doxorubicin.  
J Control Release. 1992; 19: 331–346. 
doi:10.1016/0168-3659(92)90088-9 
[14]  Hoste K, De Winne K, Schacht E.  
Polymeric prodrugs. 
Int J Pharm. 2004; 277: 119–131.  
doi:10.1016/j.ijpharm.2003.07.016 
[15]  Choi HK, Chun MK, Lee SH, Jang MH, Kim HD, Jung CS. 
In Vitro and In Vivo Study of Poly (ethylene glycol) Conjugated Ketoprofen to Extend the Duration of 
Action. 
Int J Pharm. 2007; 341: 50–57.  
doi:10.1016/j.ijpharm.2007.03.045 
[16]  Zhang J, Fan XD, Liu Y, Bo L, Liu X.  
Synthesis of poly (ethylene glycol) - metaxalone conjugates and study of its controlled release in vitro. 
Int J Pharm. 2007; 197: 125–131.  
doi:10.1016/j.ijpharm.2006.09.039 372  A. Nayak and A. Jain:   
Sci Pharm. 2011; 79: 359–373 
[17]  Bersani C, Berna M, Pasut G, Francesco VM.  
PEG-Metronidazole Conjugates: Synthesis, In vitro and In vivo Properties.  
Farmaco. 2005; 60: 783–788.  
doi:10.1016/j.farmac.2005.04.015 
[18] Namazi  H, Bahrami S, Entezami AA.  
Synthesis and Controlled Release of Biocompatible Prodrugs of β-Cyclodextrin Linked with PEG 
Containing Ibuprofen or Indomethacin. 
Iran Polym J. 2005; 14: 921–927.  
[19]  Khandare J, Minko T.  
Polymer–Drug Conjugates: Progress in Polymeric Prodrugs.  
Prog Polym Sci. 2006; 31: 359–397.  
doi:10.1016/j.progpolymsci.2005.09.004 
[20]  Dhaneshwar SS, Kandpal M, Gairola N, Kadam SS.  
Dextran: A promising macromolecular drug carrier.  
Indian J Pharm Sci. 2006; 68: 705–714.  
doi:10.4103/0250-474X.31000 
[21]  Vyas S, Trivedi P, Chaturvedi SC.  
Ketorolac-dextran conjugates: Synthesis, in vitro and in vivo evaluation. 
Acta Pharm. 2007; 57: 441–450.  
doi:10.2478/v10007-007-0035-3 
[22]  Larsen C, Johansen M.  
Macromolecular prodrugs XI: Regeneration rates of various NSAID compounds from their 
corresponding dextran ester prodrugs in aqueous buffer and in different biological media. 
Acta Pharm. 1989; 2: 57–65.  
[23]  Larsen C, Johansen M. 
Macromolecular prodrugs I. Kinetics and mechanism of hydrolysis of O-benzoyl dextran conjugate in 
aqueous buffer and human plasma. 
Int J Pharm. 1985; 27: 205–218. 
doi:10.1016/0378-5173(85)90070-5 
[24]  Zhao X, Tao X, Wei D, Song Q. 
Pharmacological activity and hydrolysis behavior of novel ibuprofen glucopyranoside conjugates.  
Eur J Med Chem. 2006, 41: 1352–1358.  
doi:10.1016/j.ejmech.2006.05.014 
[25]  Khan MSY, Akhter M.  
Synthesis, pharmacological activity and hydrolytic behavior of glyceride prodrugs of Ibuprofen.  
Eur J Med Chem. 2005; 40: 371–376.  
doi:10.1016/j.ejmech.2004.11.009 
[26]  Ghorab MK, Adeyeye MC.  
Enhancement of ibuprofen dissolution via wet granulation with beta cyclodextrin.  
Pharm Dev Technol. 2001; 6: 305–314.  
doi:10.1081/PDT-100002611 
[27]  Challa R, Ahuja A, Ali J, Khar RK.  
Cyclodextrins in Drug Delivery: An Updated Review. 
AAPS PharmSciTech. 2005; 6: E329–E357. 
doi:10.1208/pt060243 
[28]  Nichifor M, Schacht EH, Seymour LW.  
Polymeric prodrugs of 5- fluorouracil.  
J Control Release. 1997; 48: 165–178.  
doi:10.1016/S0168-3659(97)00048-5   In Vitro and In Vivo Study of Poly(ethylene glycol) Conjugated Ibuprofen to Extend the Duration …  373 
Sci Pharm. 2011; 79: 359–373 
[29]  Ozguney IS, Karasulu HY, Kantarci G, Sozer S, Guneri T, Ertan G.  
Transdermal Delivery of Diclofenac Sodium Through Rat Skin From Various Formulations. 
AAPS PharmSciTech. 2006; 7: E39–E45. 
doi:10.1208/pt070488 
[30]  Obat Y, Takayama K, Maitani Y, Machida Y, Nagai T.  
Effect of ethanol on skin permeation of nonionized and ionized diclofenac.  
Int J Pharm. 1993; 89: 191–198.  
doi:10.1016/0378-5173(93)90243-9 
[31]  Kantari G, Ozguney I, Karasulu HY, Güneri T, Başdemir G.  
In vitro permeation of diclofenac sodium from novel microemulsion formulations through rabbit skin.  
Drug Dev Res. 2005; 65: 17–25.  
doi:10.1002/ddr.20003 
[32]  Vogel GH, Vogel WH.  
In: Drug Discovery and Evaluation of Pharmacological Assays. 
Springer-Verlag: Berlin, 1997: 669–759. 
[33]  Zacchigna M, Luca GD, Cateni F, Maurich V. 
Improvement of warfarin biopharmaceutics by conjugation with poly (ethylene glycol). 
Eur J Pharm Sci. 2004; 23: 379–384.  
doi:10.1016/j.ejps.2004.09.001 
 